Island Pharmaceuticals Limited (ASX:ILA)

Australia flag Australia · Delayed Price · Currency is AUD
0.420
+0.005 (1.20%)
At close: Mar 6, 2026
162.50%
Market Cap 123.80M
Revenue (ttm) 62.85K
Net Income (ttm) -7.20M
Shares Out 294.77M
EPS (ttm) -0.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,113,243
Average Volume 421,011
Open 0.420
Previous Close 0.415
Day's Range 0.405 - 0.425
52-Week Range 0.120 - 0.630
Beta 0.13
RSI 57.49
Earnings Date Feb 22, 2026

About Island Pharmaceuticals

Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol ILA
Full Company Profile

Financial Performance

In fiscal year 2025, Island Pharmaceuticals's revenue was 118,910, a decrease of -90.57% compared to the previous year's 1.26 million. Losses were -3.92 million, 36.9% more than in 2024.

Financial Statements

News

There is no news available yet.